Different lines of evidence indicate that monitoring the blood levels of therapeutic antibodies, characterized by high inter-individual variability, can help to optimize clinical decision making, improving patient outcomes and reducing costs with these expensive treatments. A surface plasmon resonance (SPR)-based immunoassay has recently been shown to allow highly reliable and robust monitoring of serum concentrations of infliximab, with significant advantages over classical ELISA. The next level of advancement would be the availability of compact and transportable SPR devices suitable for easy, fast and cheap point-of-care analysis. Here we report the data obtained with recently developed, cost-effective, optical-fibre-based SPR sensors (SPR-POF), which allow the construction of a compact miniaturized system for remote sensing. We carried out an extensive characterization of infliximab binding to an anti-infliximab antibody immobilized on the SPR-POF sensor surface. The present proof-of-principle studies demonstrate the feasibility of the proposed SPR-POF platform for the specific detection of infliximab, in both buffer and human serum, and pave the way for further technological improvements.

不同的证据表明，以个体间高变异性为特征的监测治疗性抗体的血液水平可以帮助优化临床决策，改善患者预后并降低这些昂贵治疗的费用。最近显示，基于表面等离振子共振（SPR）的免疫测定可高度可靠和可靠地监测英夫利昔单抗的血清浓度，与传统ELISA相比具有显着优势。下一级别的进步将是提供适用于简单，快速和廉价的即时医疗分析的紧凑且可运输的SPR设备。在这里，我们报告使用最新开发的，具有成本效益的，基于光纤的SPR传感器（SPR-POF）所获得的数据，该传感器可以构建紧凑的小型化遥感系统。我们对英夫利昔单抗结合固定在SPR-POF传感器表面的抗英夫利昔单抗抗体进行了广泛的表征。本原理验证研究证明了拟议的SPR-POF平台在缓冲液和人血清中特异性检测英夫利昔单抗的可行性，并为进一步的技术改进铺平了道路。